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ABSTRACT 
In recent years, robot-assisted radical cystectomy has 
received attention worldwide as a useful procedure 
that helps to overcome the limitations of open radical 
cystectomy. We compared the surgical technique, peri-
operative and oncological outcomes, and learning curve 
of robot-assisted radical cystectomy with those of open 
radical cystectomy. The indications for robot-assisted 
radical cystectomy are identical to those of open radical 
cystectomy. Relative contraindications are due to patient 
positioning in the Trendelenburg position for long peri-
ods. Urinary diversion is performed either extracorpore-
ally with a small skin incision or intracorporeally with 
a totally robotic-assisted maneuver. Accordingly, robot-
assisted radical cystectomy can be performed safely 
with an acceptable operative time, little blood loss, and 
low transfusion rates. The lymph node yield and positive 
surgical margin rate were not significantly different be-
tween robot-assisted radical cystectomy and open radi-
cal cystectomy. The survival rates after robot-assisted 
radical cystectomy are estimated to be similar to that 
after open radical cystectomy. However, the recurrence 
pattern is different between robot-assisted radical cys-
tectomy and open radical cystectomy, i.e., extrapelvic 
lymph node recurrence and peritoneal carcinomatosis 
were more frequently found in patients who underwent 
robot-assisted radical cystectomy than in those who un-
derwent open radical cystectomy. Further validation is 
necessary to prove the feasibility of oncological control. 
A steep learning curve is one of the benefits of the new 
technique. The experience of only 50 robot-assisted 
radical prostatectomies is a minimum requirement for 
performing feasible robot-assisted radical cystectomy, 
and surgeons who have performed only 30 surgeries can 
reach an acceptable level of quality for robot-assisted 
radical cystectomy.  
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The gold standard treatment for patients with muscle-
invasive and high-risk superficial bladder cancer is open 
radical cystectomy (ORC) with pelvic lymph node dis-
section (PLND).1 However, ORC is a challenging proce-
dure requiring not only high-quality cancer control but 
also functional preservation, for which urinary diversion 
using the intestinal tract is performed. Moreover, periop-
erative morbidity of ORC is not always low, even when 
performed by an experienced surgeon, while consider-
ing the high probability of blood transfusion owing to 
extensive intraoperative bleeding, postoperative wound 
pain resulting from a longer skin incision, postopera-
tive ileus caused by prolonged open abdominal surgery 
and excessive handling of the intestinal tract, and longer 
hospitalization resulting from a delay in the recovery of 
general health.2 Therefore, some patients cannot undergo 
ORC owing to advanced age, performance status, and 
the presence of multiple comorbidities, and so on.
 Since the first report of robot-assisted radical cys-
tectomy (RARC) by Menon et al.3 in 2003, many stud-
ies have documented that RARC is less-invasive and 
equivalent in oncologic efficacy compared to ORC. In 
recent years, RARC has received attention worldwide as 
a useful procedure that helps to overcome the limitations 
of ORC.4 In the United States, the proportion of RARC 
being performed has increased steadily over the years, 
from 0.6% in 2004 to 12.8% in 2010.5 Owing to increas-
ing use of RARC, we compared the surgical technique, 
perioperative and oncological outcomes, and learning 
curve of RARC with those of ORC.
SURGICAL TECHNIQUE
Patient selection
The indications for RARC are identical to those of ORC. 
There are no absolute contraindications for RARC. 
However, we should take care not to injure the rectum 
in patients with a history of extensive pelvic surgery and 
radiation. Relative contraindications come from patient 
positioning in the Trendelenburg position over long 
period. We should carefully select patients with angle 
96
A. Takenaka
closure glaucoma, intracranial aneurysm, severe mitral 
valve insufficiency, and severe pulmonary dysfunction.
Positioning and port placement
The patient is placed in the Trendelenburg position with 
the head placed at angle of approximately 20–25°. The 
angle in RARC is less steep than that in robot-assisted 
radical prostatectomy (RARP). Except for the angle, the 
patient positioning is almost the same as in RARP. Port 
placement is also similar to that of RARP. Fig. 1 shows 
the configuration used in Tottori University. The camera 
port is placed at the midline, i.e., 18 cm from the pubic 
symphysis, which is 2–3 cm higher than that in RARP. 
Besides the configuration in RARP, a second assistant 
12 mm port is added 7 cm above from the midpoint be-
tween the camera and the left robotic port.
Technique for cystectomy
If necessary, the urethra was detached via the perineal 
approach to the genitourinary diaphragm before a con-
sole maneuver. Our RARC procedure is summarized 
as follows; i) detachment of the ureters; ii) dissection of 
the posterior surface of the bladder; iii) dissection of the 
lateral surface of the bladder; iv) cutting of the vascular 
pedicle of the bladder and ureters; v) dissection of the 
Fig. 1. Port position.
 : Camera port (12mm)
 : Robot right arm (8mm)    
 : Robot left arm (8mm)
 : Robot 4th arm (8mm)
 : 1st assistant right arm (12mm)
 : 1st assistant left arm (12mm)
 : 2nd assistant (12mm)
posterior surface of the prostate by making an incision 
of the Denonvilliers’ fascia; vi) dissection of the anterior 
surface of the bladder and prostate, by cutting the dorsal 
vein complex and vii) extraction of the urethra inside the 
pelvis. 
Technique for PLND
The area for performing PLND includes the external, 
internal, common iliac, and obturator lymph nodes.6 
Although there are some debates whether to perform 
PLND before or after cystectomy, the surgical principle 
is more critical than the order. The obliterated umbilical 
artery provides a very useful landmark and the proximal 
limit is cautiously decided with good vision.7
Urinary diversion
Urinary diversion is performed either extracorporeally 
with a small skin incision or intracorporeally with a to-
tally robotic-assisted maneuver.
 In extracorporeal urinary diversion (ECUD),8 sub-
umbilical (separate from the camera port) or periumbili-
cal (camera port) midline incision is used for extraction 
of the specimen and subsequent manipulations. Most 
surgeons prefer a 5–7 cm long subumbilical midline 
incision with a wound retractor that provides the best 
access to the ureters and the distal ileum. Care is taken 
to isolate the ileum for urinary diversion and to perform 
ureteral anastomosis especially in obese patients and in 
whom the ureters need to be resected more proximally. 
We usually perform urethro-neovesical anastomosis ro-
botically after pouch formation completion and ureteral 
anastomosis. 
 In intracorporeal urinary diversion (ICUD), bowel 
division and anastomosis is completely performed ro-
botically. Some procedures of intracorporeal neobladder 
include those by Guru,9 Jonsson,10 Gill11 and so on. To 
improve efficiency of pouch formation, several robotic 
modifications have been used. One modification is us-
ing a shorter bowel and another is when to perform 
urethroileal anastomosis, i.e., before or after pouch 
formation completion. The masterpiece of intracorpo-
real orthotopic ileal neobladder is described by Gill et 
al.11 as follows: i) 60 cm distal ileum isolation (44 cm 
for the pouch, 16 cm for the chimney); ii) detubulariza-
tion of the ileum and completion of the posterior plate; 
iii) 90° counterclockwise rotation and the urethroileal 
anastomosis; iv) anterior pouch closure and v) bilateral 
ureteroileal anastomosis to the chimney by using the 
Bricker technique with a ureteral stent.
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Perioperative outcomes
Novara et al.12 performed a systematic review and cu-
mulative analysis of perioperative outcomes and com-
plications of RARC in compared to ORC. They showed 
statistically significant differences in the operative time 
(P < 0.00001 in favor of ORC), blood loss (P < 0.00001 
in favor of RARC), transfusion (P < 0.00001 in favor 
of RARC), and in-hospital stay (P = 0.003 in favor of 
RARC), whereas the intraoperative complication rate 
was similar. Among postoperative complication, the 
rates for any grade of complications at 90 days (P < 
0.0001) and for grade 3 complications at 90 days (P = 
0.04) were in favor of RARC. However, the rates of any 
grade complications at 30 days (P = 0.09) and grade 3 
complications at 30 days (P = 0.14) as well as the 30-day 
(P = 0.18) and 90-day (P = 0.23) mortality rates were 
similar for RARC and ORC. Thus, RARC can be per-
formed safely with an acceptable operative time, little 
blood loss, and low transfusion rates. Although the risk 
of intraoperative complication is low, postoperative com-
plication and readmission after discharge are common.
ONCOLOGICAL OUTCOME
Lymphnode yields
Abaza et al.7 showed that similar template technique to 
open could be performed, i.e., external iliac, internal 
iliac, common iliac, obturator, and presacral to aortic 
bifurcation. The mean lymph node yield was 37.5. Da-
vis et al.13 reported that he removed only an additional 
4 lymph nodes with the open approach after 43 lymph 
nodes were removed robotically. The robotic procedure 
is technically safe and feasible because vascular injuries 
were rare and the lymphocele rates were 0–9%. Yuh et 
al.14 showed that there was no significant difference in 
the lymph node yield between RARC and ORC while 
considering standard, extended, and total cases, (P = 
0.20, 0.26 and 0.07, respectively).
Positive surgical margin rate
The overall positive surgical margin (PSM) rate was 
0–26% (mean, 5.6%).15, 16 According to the pathological 
stage, the PSM rate was 1–1.5% in pT2 and 0–25% in 
pT3 or higher disease. Cumulative analysis showed no 
significant difference between RARC and ORC (5% vs. 
7%, P = 0.13).
Survival and recurrence
Recently, a few reports17–19 showed the 5-year survival 
rates as an outcome was similar between RARC and 
ORC. At 1, 3 and 5 years, disease-free survival (DFS) 
was 79–96%, 67–76%, and 53–74%, respectively; can-
cer specific survival (CSS) was 88–94%, 68–83%, and 
66–80%, respectively; and overall survival (OS) was 
82–90%, 61–80%, and 39–66%, respectively.14 Table 
1 shows the oncologic outcomes followed more than 
3 years after surgery. Accordingly, the survival rates 
of RARC are similar to that of ORC. Nguyen et al.20 
reported notable differences between RARC and ORC 
considering the recurrence pattern. Within 2 years after 
surgery, there was no major difference in the local re-
currence (18% vs. 23%) and distant metastasis (29% vs. 
36%) between RARC and ORC. On multivariate analy-
sis, RARC was not a predictor of recurrence. However, 
there were distinct different patterns of distant metasta-
sis. Extrapelvic lymph node recurrence (23% vs. 15%) 
and peritoneal carcinomatosis (21% vs. 8%) were more 
frequently found in patients who underwent RARC than 
in those who underwent ORC. As the numbers of pa-
tients was small, further validation is necessary to prove 
the feasibility of oncological control. 
LEARNING CURVE
A steep learning curve is one of the benefits of a new 
technique. Hayn et al.21 examined whether the number 
of previous RARP performed by surgeons affected the 
outcomes of RARC. In surgeons who had performed 
less than 50 RARP, the operative time was longer, blood 











DFS, % CSS, % OS, %
1y 3y 5y 1y 3y 5y 1y 3y 5y
Mmeje et al, 2013 50 Multi-institutional 41.5 12 46 43 39 55 45
Khan et al, 2013 14 Prospective 84 28 14 50 75 64
Snow-Lisy et al, 2014 17 Retrospective 67 69 39
Xylinas et al, 2013 175 Retrospective 37 19 67 63 68 66
Raza et al, 2014 99 Retrospective 73.9 6 29 53 68 42
Yuh et al, 2014 162 Retrospective 52 23 76 74 83 80 61 54
Adj. chem, adjuvant chemotherapy; CSS, cancer specific survival; DFS, disease-free survival; mo, month; Neoadj. chem, neoadjuvant 
chemotherapy; no., number; OS, overall survival; y, year.
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loss was more, and lymph node yield was lesser com-
pared to those who had performed more than 50 RARP. 
Therefore, the experience of only 50 RARP is a mini-
mum requirement for performing RARC of a certain 
quality. Hayn et al.22 also demonstrated the actual learn-
ing curve for RARC in another study. It was estimated 
that 21 patients were required for the operative time to 
reach 6.5 h, 30 patients for a lymph node yield of 20, 30 
patients for the PSM rate to be less than 5%, and 24 pa-
tients for the PSM rate to be less than 15% in pathologic 
T3–4 patients. However, the mean estimated blood loss 
was only 408 ml, and the learning curve was nearly flat. 
The study demonstrated an acceptable level of proficien-
cy by only the 30th case for proxy measures of RARC 
quality.  
CONCLUSIONS
Remarkable progress has been made in RARC with 
PLND and urinary diversion. RARC can be safely 
performed by a surgeon who has performed more than 
50 RARP. However, recent data showed different onco-
logical outcomes considering the different recurrence 
patterns from ORC. Further studies about the outcomes 
considering the recurrence patterns and long-term sur-
vival data are required. 
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